Company overview
What does PETMED EXPRESS INC do?
PETMED EXPRESS INC (PETS) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 5912 (Retail-Drug Stores and Proprietary Stores).
What does PETMED EXPRESS INC do?
PETMED EXPRESS INC (PETS) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 5912 (Retail-Drug Stores and Proprietary Stores).
What industry is PETMED EXPRESS INC in?
Consumer · Retail-Drug Stores and Proprietary Stores
What was PETMED EXPRESS INC's latest reported revenue?
$41M for Q2 2026, from 10-Q filed Aug 13, 2026.
What changed in the latest comparable period?
Revenue declined -19.9% ($51.2M to $41.0M; Q2 2025 vs Q2 2026).
Business model (from the public record)
Belvedere describes the business using the issuer’s SEC classification and the company description extracted from public filings. Segment mix, customer identity, and recurring-versus-transactional revenue are shown only when those facts are identified in the filing extract—not inferred.
Consumer · Retail-Drug Stores and Proprietary Stores · United States
Financial profile
- Revenue
- $41M 10-Q · Q2 2026 · Filed Aug 13, 2026
- Revenue growth YoY
- -19.9% Belvedere calculation · 10-Q · Q2 2026 · Filed Aug 13, 2026
- Gross margin
- +27.6% Belvedere calculation · 10-Q · Q2 2026 · Filed Aug 13, 2026
- Operating margin
- -15.2% Belvedere calculation · 10-Q · Q2 2026 · Filed Aug 13, 2026
- Net income
- -$6.1M 10-Q · Q2 2026 · Filed Aug 13, 2026
- Operating cash flow
- -$7.7M 10-Q · Q2 2026 · Filed Aug 13, 2026
- Capex
- $641,000 10-Q · Q2 2026 · Filed Aug 13, 2026
- Belvedere FCF
- -$8.3M Belvedere calculation · 10-Q · Q2 2026 · Filed Aug 13, 2026
- FCF margin
- -20.3% Belvedere calculation · 10-Q · Q2 2026 · Filed Aug 13, 2026
- Cash
- $13.1M 10-Q · Jun 30, 2026 · Filed Aug 13, 2026
- Debt
- — Not identified in latest matched XBRL period
- Net debt
- -$13.1M Belvedere calculation · 10-Q · Jun 30, 2026 · Filed Aug 13, 2026
- Shares
- 21,682,381 10-Q · Jun 30, 2026 · Filed Aug 13, 2026
Balance sheet snapshot
Cash $13.1M. Identified debt —. Net debt -$13.1M. Missing debt tags are not treated as a zero-debt capital structure.
Financial information is derived from public filings and other identified sources. Belvedere calculations may differ from company-defined non-GAAP measures. See methodology and source notes. Valuation multiples are omitted because a licensed market-data provider is not configured.
Latest filings
| Form | Filed | Period | Accession | Source |
|---|---|---|---|---|
| 8-K | Sep 17, 2026 | Sep 17, 2026 | 0001040130-26-000045 | SEC |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | 0001040130-26-000041 | SEC |
| 8-K | Aug 13, 2026 | Aug 13, 2026 | 0001040130-26-000040 | SEC |
| 8-K | Aug 12, 2026 | Aug 11, 2026 | 0001040130-26-000036 | SEC |
| 8-K | Jul 23, 2026 | Jul 23, 2026 | 0001040130-26-000029 | SEC |
| 8-K | Jun 26, 2026 | Jun 23, 2026 | 0001040130-26-000027 | SEC |
| DEF 14A | Jun 25, 2026 | Aug 11, 2026 | 0001040130-26-000023 | SEC |
| 10-K | Jun 2, 2026 | Mar 31, 2026 | 0001040130-26-000019 | SEC |
| 8-K | Jun 2, 2026 | Jun 2, 2026 | 0001040130-26-000016 | SEC |
| 8-K | May 21, 2026 | May 15, 2026 | 0001040130-26-000010 | SEC |
| 10-Q | Feb 5, 2026 | Dec 31, 2025 | 0001040130-26-000007 | SEC |
| 8-K | Jan 23, 2026 | Jan 21, 2026 | 0001040130-26-000002 | SEC |
| 8-K/A | Dec 29, 2025 | Dec 8, 2025 | 0001040130-25-000112 | SEC |
| 10-Q | Dec 19, 2025 | Sep 30, 2025 | 0001040130-25-000108 | SEC |
| 10-Q | Dec 19, 2025 | Jun 30, 2025 | 0001040130-25-000106 | SEC |
| DEF 14A | Dec 10, 2025 | Jan 21, 2026 | 0001040130-25-000099 | SEC |
| 8-K | Dec 9, 2025 | Dec 8, 2025 | 0001040130-25-000097 | SEC |
What changed
Each line is an arithmetic comparison of sourced facts. It is not a thesis.
Research view
Belvedere has not published an initiation or update on PETMED EXPRESS INC. Universe inclusion is not a rating, a forecast, or coverage in the sell-side sense.
Research Radar
| Kind | Change | Explanation | Source | Date |
|---|---|---|---|---|
| Revenue | -19.9% | Revenue declined -19.9% ($51.2M to $41.0M; Q2 2025 vs Q2 2026). | 10-Q · RevenueFromContractWithCustomerExcludingAssessedTax | Aug 13, 2026 |
| Margin change | $0.276 | Reported gross margin was +27.6% in the latest comparable period. | 10-Q · BelvedereGrossMargin | Aug 13, 2026 |
| Cash generation | $-7.7M | Net cash used in operating activities was -$7.7M. | 10-Q · NetCashProvidedByUsedInOperatingActivities | Aug 13, 2026 |
| Cash | $13.1M | Cash and cash equivalents were $13.1M as of the latest reported balance-sheet date. | 10-Q · CashAndCashEquivalentsAtCarryingValue | Aug 13, 2026 |
| Share count | $21.7M | Shares outstanding were 21,682,381 as of the latest reported date. | 10-Q · CommonStockSharesOutstanding | Aug 13, 2026 |
Rankings
- Highest Free Cash Flow Margins · rank 20 · -20.3%
- Strongest Balance Sheets · rank 26 · +20.5%
- Micro-Cap Proxy Companies by Revenue Growth · rank 12 · -19.9%
Industry context
PETMED EXPRESS INC is mapped to Consumer (Retail-Drug Stores and Proprietary Stores) from SIC metadata on the SEC submission. Mapping is a classification convenience, not a claim that every peer is economically comparable.
Belvedere Research Profile
This measures researchable information characteristics. It is not investment advice, a credit rating, or a buy/sell/hold recommendation.
Presence of core income-statement, cash-flow and balance-sheet concepts in SEC XBRL.
Comparable-period revenue history and operating-result availability.
Availability of margin, cash-flow and per-share concepts used in screening.
SEC periodic reports, current reports, proxy statement and website identified in submissions.
Distinct filing years in the current archive window plus comparable prior-period revenue.
Risks
Belvedere does not manufacture generic risk language. Material risks are those the issuer discloses in its periodic reports, particularly Item 1A of the latest Form 10-K.
Open latest Form 10-K on SEC.govSources
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q2 2026
- Filed
- Aug 13, 2026
- Accession
- 0001040130-26-000041
- Concept
- RevenueFromContractWithCustomerExcludingAssessedTax
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q2 2026
- Filed
- Aug 13, 2026
- Accession
- 0001040130-26-000041
- Concept
- BelvedereRevenueGrowthYoY
(RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30 / RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30) - 1
View filing- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q2 2026
- Filed
- Aug 13, 2026
- Accession
- 0001040130-26-000041
- Concept
- BelvedereFreeCashFlow
Net cash provided by operating activities − payments to acquire property, plant and equipment
View filing- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Jun 30, 2026
- Filed
- Aug 13, 2026
- Accession
- 0001040130-26-000041
- Concept
- CashAndCashEquivalentsAtCarryingValue
Disclosure
Belvedere Research publishes informational analysis. Nothing on this site is investment advice, an offer, or a solicitation to buy or sell any security.
This page is a company intelligence / data profile. It is not a research report unless a dated note is attached above. Rankings appearing here are independent of any issuer compensation.
Frequently asked questions
- What does PETMED EXPRESS INC do?
- PETMED EXPRESS INC (PETS) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 5912 (Retail-Drug Stores and Proprietary Stores).
- What industry is PETMED EXPRESS INC in?
- PETMED EXPRESS INC is classified in Consumer (Retail-Drug Stores and Proprietary Stores).
- When did PETMED EXPRESS INC last file a periodic report?
- PETMED EXPRESS INC last filed a 10-Q on Aug 13, 2026 (accession 0001040130-26-000041).
- What was PETMED EXPRESS INC's latest revenue?
- $41M for Q2 2026, sourced from 10-Q filed Aug 13, 2026.
- Does Belvedere cover PETMED EXPRESS INC?
- PETMED EXPRESS INC is in the Belvedere universe. Presence in the universe is not the same as active initiation coverage.